Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATYR Stock Forecast 2025-2026
$3.35
Current Price
$306.56M
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ATYR Price Targets
+944.8%
To High Target of $35.00
+392.5%
To Median Target of $16.50
+168.7%
To Low Target of $9.00
ATYR Price Momentum
+2.1%
1 Week Change
+7.0%
1 Month Change
0.0%
1 Year Change
-7.5%
Year-to-Date Change
-28.1%
From 52W High of $4.66
+135.9%
From 52W Low of $1.42
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching aTyr Pharma (ATYR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ATYR and similar high-potential opportunities.
Latest ATYR Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ATYR has a bullish consensus with a median price target of $16.50 (ranging from $9.00 to $35.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $3.35, the median forecast implies a 392.5% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 944.8% upside. Conversely, the most conservative target is provided by Roger Song at Jefferies, suggesting a 168.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATYR Analyst Ratings
11
Buy
0
Hold
0
Sell
ATYR Price Target Range
Low
$9.00
Average
$16.50
High
$35.00
Current: $3.35
Latest ATYR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATYR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Feb 18, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $16.00 |
| Jan 6, 2025 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Initiates | $0.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Oct 29, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Oct 4, 2024 | Wells Fargo | Derek Archila | Overweight | Initiates | $17.00 |
| Sep 5, 2024 | Jefferies | Roger Song | Buy | Initiates | $9.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Aug 14, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $16.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $35.00 |
| May 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Mar 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Mar 15, 2024 | RBC Capital | Outperform | Maintains | $0.00 | |
| Feb 21, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 |
Atyr Pharma Inc. (ATYR) Competitors
The following stocks are similar to aTyr Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Atyr Pharma Inc. (ATYR) Financial Data
Atyr Pharma Inc. has a market capitalization of $306.56M with a P/E ratio of -3.9x. The company generates $235,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -28,899.6% and return on equity of -79.9%.
Valuation Metrics
Market Cap
$306.56M
Enterprise Value
$238.65M
P/E Ratio
-3.9x
PEG Ratio
-4.2x
Price/Sales
1,304.5x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-28,899.6%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+24.2%
Current Ratio
5.5x
Debt/Equity
19.0x
ROE
-79.9%
ROA
-39.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Atyr Pharma Inc. (ATYR) Business Model
About Atyr Pharma Inc.
What They Do
Develops therapeutics using innovative biological pathways.
Business Model
Atyr Pharma Inc. operates in the biotechnology sector, focusing on developing novel therapeutics based on extracellular proteins known as tRNA synthetases. The company generates revenue through partnerships and collaborations with academic institutions and industry players, advancing its scientific discoveries into clinical testing for diseases with unmet medical needs, particularly fibrotic lung diseases, cancer, and inflammation-related disorders.
Additional Information
Headquartered in San Diego, California, Atyr Pharma is dedicated to making significant contributions to medical research and development, particularly in areas requiring therapeutic advancements. Its lead program targets interstitial lung diseases, positioning the company for potential impactful innovations in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
56
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Country
United States
IPO Year
2015
Website
atyrpharma.comAtyr Pharma Inc. (ATYR) Latest News & Analysis
Latest News
Quick Summary
aTyr Pharma will participate in two investor conferences in April 2025: Jones Healthcare and Technology Innovation Conference (April 8-9, Las Vegas) and Piper Sandler Spring Biopharma Symposium (April 17, Boston).
Why It Matters
aTyr Pharma’s participation in key investor conferences signals potential interest and engagement with the investment community, possibly influencing stock perception and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
aTyr Pharma approved stock options for three employees, granting 43,800 shares at $3.69 each, aligning with Nasdaq rules to incentivize new hires.
Why It Matters
The stock option grants indicate aTyr Pharma's commitment to attracting talent, which could drive innovation and growth, affecting future profitability and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
1 month ago
Quick Summary
aTyr Pharma appointed Dalia R. Rayes as Head of Commercial for its Global Efzofitimod Franchise, enhancing leadership in its tRNA synthetase platform development.
Why It Matters
The appointment of Dalia R. Rayes as Head of Commercial for efzofitimod signals a strategic focus on commercializing aTyr's product, potentially boosting future revenue and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have had performance metrics compared to their sector for the year, specifics not provided in the excerpt.
Why It Matters
Performance comparisons highlight Atyr Pharma and Delcath Systems' market positioning, influencing investor sentiment and potential stock valuation within their sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
aTyr Pharma, Inc. will host its Q4 2024 Earnings Conference Call on March 13, 2025, at 5:00 PM ET, featuring key executives and analysts from major financial firms.
Why It Matters
The Q4 earnings call schedule indicates upcoming financial performance insights, which can influence stock price, investor sentiment, and strategic decisions based on company projections.
Source: Seeking Alpha
Market Sentiment:
Neutral
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
1 month ago
Quick Summary
Phase 3 EFZO-FIT™ study data for efzofitimod in pulmonary sarcoidosis is expected in Q3 2025. A fourth DSMB review confirms its favorable safety profile.
Why It Matters
Positive DSMB reviews and upcoming Phase 3 data for efzofitimod indicate strong potential for market approval, influencing stock performance and investor sentiment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ATYR Stock
What is Atyr Pharma Inc.'s (ATYR) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Atyr Pharma Inc. (ATYR) has a median price target of $16.50. The highest price target is $35.00 and the lowest is $9.00.
Is ATYR stock a good investment in 2025?
According to current analyst ratings, ATYR has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATYR stock?
Wall Street analysts predict ATYR stock could reach $16.50 in the next 12 months. This represents a 392.5% increase from the current price of $3.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atyr Pharma Inc.'s business model?
Atyr Pharma Inc. operates in the biotechnology sector, focusing on developing novel therapeutics based on extracellular proteins known as tRNA synthetases. The company generates revenue through partnerships and collaborations with academic institutions and industry players, advancing its scientific discoveries into clinical testing for diseases with unmet medical needs, particularly fibrotic lung diseases, cancer, and inflammation-related disorders.
What is the highest forecasted price for ATYR Atyr Pharma Inc.?
The highest price target for ATYR is $35.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 944.8% increase from the current price of $3.35.
What is the lowest forecasted price for ATYR Atyr Pharma Inc.?
The lowest price target for ATYR is $9.00 from Roger Song at Jefferies, which represents a 168.7% increase from the current price of $3.35.
What is the overall ATYR consensus from analysts for Atyr Pharma Inc.?
The overall analyst consensus for ATYR is bullish. Out of 7 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.50.
How accurate are ATYR stock price projections?
Stock price projections, including those for Atyr Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:39 AM UTC